Malignant melanoma is one of the most aggressive human cancers but the mechanisms governing its metastatic dissemination are not fully understood. Upregulation of miR-214 and ALCAM and the loss of TFAP2 expression have been implicated in this process, with TFAP2 a direct target of miR-214.
INTRODUCTION
Malignant melanoma represents the fifth most common neoplasia in human and is one of the most invasive, therapy-resistant and metastatic tumors, with only about 10% survival, 5 years postdiagnosis (1) . Over the past decades, its incidence has been increasing by 3-8% per year in Western countries while mortality has stabilized. Therefore, it is essential to unravel the molecular events that regulate melanoma aggressiveness and metastatic dissemination. Melanoma progresses rapidly through a radial growth phase, confined entirely in the epidermis, followed by a subsequent vertical growth phase, corresponding to the high-risk melanomas, characterized by invasion of the epidermis upper layer, deep infiltration of the dermis and subcutaneous tissues and formation of lymph-nodal, cutaneous and visceral metastases in a vast majority of cases (2, 3) . The transition from the noninvasive to the invasive and metastatic stage is accompanied by specific and well-characterized molecular changes, such as loss of the AP-2 transcription factors (TFAP2) and expression alterations for genes involved in adhesion, angiogenesis, invasion and survival, including MCAM-MUC-18, ALCAM, E-cadherin, N-cadherin, VEGF, IL-8, MMP2 and c-KIT (3) . Moreover, BRAF V600E oncogenic mutation is one of the earliest and common molecular events that characterize malignant melanoma (2) .
The activated leukocyte cell adhesion molecule, ALCAM/CD166, is a transmembrane glycoprotein, member of the immunoglobulin superfamily, involved in both homotypic and heterotypic (to CD6) cell adhesion (4) . ALCAM cis-oligomerization on the cell surface and trans-intercellular interactions synergistically promote network formation at site of cell-cell contacts (5, 6) . ALCAM expression is altered in many types of tumors, including melanomas, where it is considered as a prognostic molecular marker for neoplastic progression (7) . Indeed, while ALCAM expression is low or absent in nevi, in situ and thin melanomas, ALCAM is detectable in the vertical growth phase melanomas and in metastatic lesions. Significantly, the fraction of ALCAM positive lesions increases according to 4 invasiveness (Clark level) and thickness (Breslow index) of the melanocytic tumor (8) . It was shown that any interference with ALCAM function affects melanoma cell movement and invasion (9, 10) and that ALCAM triggers matrix metalloproteinase (MMP2 and MMP14) activity (11) . However, it is still not known how ALCAM overexpression is induced in melanomas and how it coordinates metastasis formation.
microRNAs (miRs) are small endogenous non-coding RNAs that deeply contribute to tumor formation and progression, for their ability to post-transcriptionally downregulate the expression of specific target genes by binding to the 3'UTRs of their mRNAs, causing degradation or translation inhibition (12) (13) (14) (15) .
Several miRs, including miR-137, miR-221/222, miR-182 and miR-34a, have been found to be involved in melanoma progression by regulating key genes such as c-KIT, MITF, FOXO3, ITGB3, CCND1 and p27 Kip1 (16) . By using a melanoma progression model (17) , consisting of a poorly metastatic human melanoma A375P parental cell line and its highly metastatic variants (MA-2, MC-1),
we recently demonstrated that miR-214 coordinates melanoma metastasis dissemination by increasing migration, invasion, extravasation and survival of melanoma cells. In addition, we identified a pathway coordinated by miR-214 and involving TFAP2A and TFAP2C as well as multiple adhesion molecules, including ALCAM (18) . Here, we show that miR-214 mediates ALCAM upregulation by silencing TFAP2 and miR-148b, both negative regulators of ALCAM. More importantly, we present evidences that some miR-214-mediated pro-metastatic functions are directly exerted by ALCAM. 
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MATERIALS AND METHODS
Cell culture
A375P, MA-2 and MC-1 cells were provided by R.O. Hynes and maintained as described (17, 18) . WKMel, SK-Mel-28 and HUVECs-GFP were provided by P. Circosta, L. Poliseno and L. Primo, respectively and maintained as described (19) (20) (21) . MDA-MB-231 were from ATCC. All the cell lines used were authenticated in the last 6 months by BMR Genomics (Padova, Italy) using the CELL ID System (Promega, Madison, WI). BRAF V600E mutation was previously described (21) or assessed by sequencing and pyrosequencing analyses as described in (22) . Transient transfections and generation of stable cell lines by lentiviral infections were performed as described (18) .
Reagents, antibodies, vectors, primers, RNA, protein and human melanoma samples analyses
pLemiR-empty and pLemiR-214 expression vectors were described in (18 
In vitro biological assays
Migration, invasion, proliferation, anchorage-independent growth, transendothelial migration and anoikis assays were previously described in (18) .
In vivo metastasis assays
All experiments performed with live animals complied with ethical animal care. For experimental metastasis assays, 5x10 5 (1:100 dilution) and specimens examined using a Zeiss AxioObserver microscope with the ApoTome Module. (18) .
In silico analyses
TFAP2 putative binding sites were obtained by the classical Positional Weight Matrices (PWM) approach (23), as described in (24) . TFAP2 matrix was obtained from the JASPAR CORE database and background nucleotide frequencies were derived from the analyzed sequence. We considered high affinity sites those with a score higher than 80% of the maximum score (i.e. the score of the perfect match for the PWM) and low affinity sites those below 80% but over 60%. To assess direct interactions between miR-214 and miR-148b we evaluated 2000 nucleotides upstream and downstream of pre-miR-148b, considering the mean lengths of pri-miRs reported in (25) . RNA Hybrid algorithm (26) was used, either with or without the option that forces to obtain a perfect helix in the 2-7 region of the seed. The p-value was estimated using as background either the human intronic dinucleotides frequencies or the default 3'UTR based ones. p>0.05 was considered non-statistically significant. The result was confirmed by LALIGN manual alignment program.
Statistical analyses
Data are presented as mean ± Standard Deviation (SD) or as mean ± Standard Error of Mean (SEM), as indicated, and two tailed Student's t test was used for comparison, with * =p<0.05; ** = p<0.01; ***= p<0.001 considered to be statistically significant. ns indicates a non-statistically significant pvalue.
All reagents, antibodies, vectors and primer sequences employed in this study, as well as detailed experimental procedures are described in Supplementary Materials and Methods. 
RESULTS
ALCAM is upregulated by miR-214 in melanoma
As summarized in Table S1 , here and previously (18) migration in vitro and, while no effects were observed for serum-dependent proliferation (Fig. S2B ), a significant enhancement or reduction of cell movement was observed for ALCAM overexpressing (Fig.   1E ) or silenced ( Fig. 1F and G) cells, compared to controls, thus phenocopying miR-214 expression modulations (18) . To assess whether the pro-metastatic phenotype associated to miR-214 overexpression in melanoma cells could be rescued, at least in part, by ALCAM silencing, we silenced ALCAM in a transient manner by siRNAs (Fig 1H, WK 1H-L), while no effect on MA-2 serum-dependent proliferation (Fig. S2C ) or anchorage-independent growth in soft agar ( Fig. S2D ) was found, leading us to conclude that ALCAM is able to rescue miR-214-induced increase in cell movement.
As previously shown for MA-2 cells (18) following subcutaneous injection of miR-214-overexpressing ALCAM-silenced MA-2 cells in NSG mice, looking for red fluorescent microscopic metastatic lesions 7 weeks later. Primary tumor growth was also evaluated here and no difference was found (Fig. 2D, top) . However, as shown in Fig. 2D (bottom, a-c), the increased number of lung micrometastases found for miR-214-overexpressing cells was significantly rescued when ALCAM was silenced. Very few metastatic lesions were observed in the livers.
Since these in vitro and in vivo results were obtained for three distinct melanoma cell lines and independently of BRAF V600E mutation status (Table S1) 
miR-214-driven ALCAM upregulation in melanoma cells partially depends on TFAP2-mediated transcriptional repression
To identify the molecular mechanisms leading to ALCAM upregulation by miR-214, we first considered a possible transcriptional regulation. We previously demonstrated that the transcription factors TFAP2A and TFAP2C are targeted by miR-214 in MA-2 cells (18); we now observed relevant TFAP2A and TFAP2C downmodulation by miR-214 also in WK-Mel and SK-Mel-28 cells (Fig 4A) . Thus, we silenced cells (pLKO-shTFAP2C) we observed 20% increased ALCAM protein expression compared to control (pLKO-empty), as shown in Fig. 4E . These results suggested that miR-214-driven ALCAM upregulation could depend on TFAP2A and/or TFAP2C decrease due to miR-214 targeting. In line with this, we observed lower ALCAM levels in miR-214-overexpressing (pLemiR-214) MA-2 cells when TFAP2A or, to a lesser extent, TFAP2C (pSP(RSV)-TFAP2A, pSP(RSV)-TFAP2C) or both were overexpressed compared with controls (Fig. 4F) . The ALCAM promoter region, from -900 to +100 bps relative to the transcription start site (TSS), was analysed with bioinformatics tools, using the canonical TFAP2 binding site Position Weight Matrix (PWM) consisting of a 9 nucleotide long G/C-rich sequence, shared for TFAP2A and TFAP2C. 5 putative TFAP2 binding sites (BS) were identified, with high affinity binding scores, at positions -316 (BS5), -249 (BS4), -208 (BS3), -163 (BS2) and -126 (BS1) (Fig. 4G) . A chromatin immunoprecipitation (ChIP) experiment was performed using crosslinked MA-2 chromatin, with negative (IgG) or positive (RNA Polymerase II, PolII) control or anti-TFAP2 (recognizing both TFAP2A and TFAP2C) antibodies. Importantly, by PCR-amplifying the region containing the 5 TFAP2 binding sites, more than 4-fold TFAP2 binding enrichment was observed on this region relative to IgG negative control (Fig. 4H) . As a positive control PolII-immunoprecipitated DNA was tested with a GAPDH promoter PCR assay (Fig. S3A) . To test the direct effect of TFAP2 on ALCAM promoter, the activity of the promoter region between -753 and +35 relative to the TSS, was assayed in a Luciferase reporter vector (pGL3-ALCAMprom). MA-2 cells were co-transfected with either pGL3-ALCAMprom or pGL3-empty and TFAP2A and/or TFAP2C expression constructs or empty control (pSP(RSV)-TFAP2A, pSP(RSV)-TFAP2C, or pSP(RSV)-empty) and Luciferase activity was evaluated 48h (Fig. 4I) and 72h (Fig. S3B) post-transfection. pGL3-ALCAMprom Luciferase activity was normalized on pGL3-empty activity in a condition of TFAP2 overexpression. As a positive control, a Luciferase construct containing the known TFAP2A-responsive ESDN promoter region (24) was used (Fig. S3C ). pGL3-ALCAMprom activity was significantly decreased in presence of TFAP2A or TFAP2C or both (60% to 40% reduction), compared to pSP(RSV)-empty control, indicating a direct transcriptional repression of TFAP2 on ALCAM promoter (Fig. 4I, left) 
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binding sites one-by-one (del_5 to del_1) were not able to rescue the Luciferease activity, while when we deleted 2 or 3 binding sites in combinations (del_3+5, del_2+3, del_2+3+5) or the entire promoter region included between -316 and -126 thus eliminating all the 5 binding sites (del_all), we were able to abrogate the Luciferease activity decrease in presence of TFAP2 (Fig.4I, right) (Fig. 5A-C) . To investigate the direct binding of miR-148b on ALCAM, the first 605 bps of ALCAM 3' UTR (Fig. 5F ), containing miR-148b putative binding site (at position 272-277), was cloned in the pMIR-REPORT reporter vector downstream of the Luciferase coding sequence (ALCAM3'UTR). miR-148b binding site was also mutated (point mutations or deletion, shown in Fig. 5F ) to generate mutant ALCAM 3' UTRs (ALCAMmut and ALCAMdel). Luciferase activity of wild type (WT) or mutant vectors was evaluated in MA-2 cells in presence or absence of miR-148b overexpression (pre-miR148b or -control). A significant decrease of Luciferase activity was observed for the WT but not for the mutants in presence of miR-148b compared to controls, indicating the specific regulation of miR-148b on ALCAM 3'UTR (Fig. 5G) . As a positive control, a miR-148b sensor construct containing three perfect bindings for miR-148b was used (Fig. 5G) . Importantly, when we analysed miR-148b levels in miR-214-overexpressing (pre-miR-214) MA-2, WK-Mel, SK-Mel-28 and MDA-MB-231 cells, a significant reduction of miR-148b expression was found at 24h, 48h (Fig. S3D , MA-2) and 72h ( CAN-12-3686 control), as evaluated by qRT-PCR. A similar miR-148b reduction was obtained in stable miR-214-overexpressing (pLemiR-214) MA-2 (Fig. 5l) or WK-Mel (Fig. 5J ) cells, compared with empty control (pLemiR-empty). Consistently, miR-148b expression levels were increased in presence of anti-miR-214 in MC-1 cells, compared with anti-control-transfected cells (Fig. 5L) . Other unrelated miRs, for instance miR-31, were not affected by miR-214 overexpression (Fig. 5M) . These data suggest a regulatory loop between miR-214 and miR-148b, which can affect ALCAM expression. Indeed, the concomitant overexpression of miR-148b and miR-214 (pre-miR-214+pre-miR-148b transfection) in MA-2 cells (Fig. S1C) or the re-expression of miR-148b in stable miR-214-overexpressing cells (pLemiR-214+pre-miR-148b; Fig. S1D ) led to reduced ALCAM protein ( Fig. 5A and D) and mRNA ( Fig. 5E ) levels, similar to control cells (pre-control or pLemiR-empty+pre-control, respectively).
miR-148b downregulation by miR-214 is partially due to TFAP2 control
In order to explore how miR-214 downregulates miR-148b, we performed a bioinformatics analysis for miR-148b containing human genomic locus (2000 nucleotides upstream and downstream of pre-miR148b), inside the intron 1 of COPZ1 protein-coding gene. First, as described in (28), we used RNA Hybrid algorithm (26) to look for in silico evidences of a direct interaction between miR-214 and miR148b transcript, potentially involved in controlling processing or stability. A single putative 20-nucleotide long miR-214 binding site was found 650 nucleotides downstream of the pre-miR-148b locus ( Fig. 6A and B) , but with a non-statistically significant (ns) p-value (independently of the method used to estimate it, see Materials and Methods and Fig. 6B ), leading us to exclude its relevance in this mechanism. Instead, when we looked for putative TFAP2 binding sites in pre-miR-148b flanking regions, many low-and three high-affinity sites were found, including one located 1816 nucleotides upstream of the pre-miR-148b, having 83% of the maximum PWM score, with a potential role in controlling its transcription (Fig. 6A and C, top) . Importantly, as indicated in Fig. 6C performed ChIP experiments in MA-2 cells, as described above, and confirmed TFAP2A/C binding enrichment (1.9-fold) in this region (Fig. 6D ), compared to IgG negative control. These results suggest that the miR-214 regulation on miR-148b is at least partially due to TFAP2-mediated control on miR148b. Indeed, also miR-148b primary transcript (pri-miR-148b) evaluated by qRT-PCR, was about 30% reduced in miR-214 (pre-miR-214) overexpressing MA-2 cells (Fig. 6E) and, consistently, both pri- (Fig. 6F and G) and mature ( Fig. 6H and I ) miR-148b levels were more than 50% increased following overexpression of TFAP2A and TFAP2C. Taken together our data indicate that TFAP2A has a dual role on ALCAM regulation, as summarized in Fig. 6J : it binds on ALCAM promoter and represses ALCAM transcription; it controls ALCAM-targeting miR-148b expression.
miR-148b opposes miR-214-mediated pro-metastatic functions in melanoma
Since we observed that ALCAM upregulation by miR-214 is at least in part due to miR-148b reduction, we explored the functions of miR-148b in melanoma cell movement. miR-148b was transiently overexpressed in MA-2 and WK-Mel cells by pre-miR-148b transfection and cell migration was evaluated by transwell assays. Significantly, miR-148b overexpression led to decreased cell movement compared to pre-control ( Fig. 7A and B) . Consistently, miR-148b silencing by anti-miR148b (Fig. S1F ) resulted in increased cell migration, compared with anti-control transfected cells (Fig. 7C ).
More importantly, as shown in Fig. 7D , the concomitant overexpression of miR-148b in miR-214-overexpressing MA-2 cells (pLemiR-214+pre-miR-148b) was able to rescue miR-214-induced increased cell migration (pLemiR-214+pre-control) similarly to control cells (pLemiR-empty+pre-control). We also observed that survival to anoikis was decreased (Fig. S3G) . We then tested transendothelial migration, as described above, and we observed decreased ability of MA-2 cells to migrate through the HUVECs-GFP monolayer when miR-148b was overexpressed (pre-miR-148b) compared with pre-control, opposite to pre-miR-214 transfected cells (Fig. 7E) . Remarkably, concomitant miR-148b and miR-214 overexpression (pre-miR-214+pre-miR-148b) completely rescued miR-214-mediated transendothelial migration (Fig. 7E) . When we evaluated early lung colonization in when miR-148b was upregulated in miR-214-overexpressing cells (pre-miR-214+pre-miR-148b), we observed a rescuing of miR-214-induced cell extravasation and early lung colonization (Fig. 7F), suggesting a role for miR-148b in miR-214/ALCAM-mediated melanoma cell metastatic dissemination.
In conclusion, miR-148b is downregulated by miR-214, at lest in part via a TFAP2-driven mechanism, and these two small RNAs exert opposite roles in melanoma cell dissemination, by controlling ALCAM expression. These observations are strengthened by the analysis of miR-214, miR-148b, ALCAM and TFAP2 in human melanoma patients. We took advantage of the same cohort of patients used in (18, 30) . As indicated in Fig. 7G (bottom) , we previously demonstrated that miR-214 was significantly more expressed, while TFAP2A and TFAP2C were less expressed, in invasive melanoma samples compared with non-invasive (in situ) ones, by qRT-PCR and immunoistochemical analyses respectively (18, 30) . In a subgroup of the same samples, we now evaluated ALCAM mRNA expression by qRT-PCR and found a significant increase in invasive melanomas (n=16) compared to in situ tumors (n=6) (Fig. 7G, top) , thus reinforcing our findings. Importantly, when we considered miR148b/miR-214 expression ratio by qRT-PCR in this cohort (Fig. 7G, middle) and in a new independent cohort of melanoma patients (n= 10 in situ and n=10 invasive; Fig. S4, top) we consistently found low miR-148b (less than 10%) and high miR-214 relative levels, indicating that miR-148b is maintained low in high miR-214 expressing melanomas, at lest partially by the above described miR-214- 
DISCUSSION
We previously demonstrated a pro-metastatic function for miR-214 in melanoma (18) . The present work spotted light on the link between miR-214 and ALCAM in the coordination of melanoma progression. Here, we showed that ALCAM expression increases when miR-214 is upregulated in several different melanoma cell lines, independently of BRAF V600E mutation status. Previously, we found increased levels of miR-214 in metastatic melanoma cells compared to their poorly malignant counterparts and in invasive or metastatic human melanomas but not in in situ samples (18) .
Supporting the connection between miR-214 and ALCAM are the immunohistochemical analyses for ALCAM in human melanoma samples, which show a perfect correlation between higher levels of ALCAM and thicker lesions or later tumor stages, from common nevi to metastases (8) . ALCAM expression was specifically detected at the invasive front of melanomas (8) . Moreover, here we highlighted increased ALCAM mRNA expression in invasive high miR-214-expressing human melanomas, compared with in situ lesions. In addition, ALCAM resulted to be highly expressed in xenotransplants and metastases originated in mice following injection of melanoma cell variants with high levels of miR-214 (17) . Finally, ALCAM expression associates with poor prognosis or relapse for other human tumors, including colorectal, bladder, esophageal and intraductal breast carcinomas (7, 31, 32) and high ALCAM or miR-214 serum levels are considered poor prognostic markers for some kind of neoplasia (33) (34) (35) (36) .
ALCAM has a key role in normal tissue or tumor integrity, in heterotypic tumor cell-endothelial cell interactions and in immune cell attachment and transmigration through vessels (5, 6, 37), therefore it is fundamental for primary tumor mass growth and tumor escaping. ALCAM connections are essential for cell movement (9), for efficient conversion of pro-MMP-2 to its active form in metastatic melanoma cells (11) and for the retention of intravascular breast tumor cell clusters in the lung vessels (38) .
Consistently, we demonstrated that ALCAM overexpression promotes cell migration while silencing CAN-12-3686 binding site or of combinations of them or of the entire region encompassing the 5 sites suggests their cooperative action. In fact, the ablation of multiple or all sites was able to abrogate TFAP2-dependent Luciferase activity reduction. Decreased levels of ALCAM, comparable to low miR-214-expressing cells, were seen in miR-214-overexpressing cells following TFAP2A and, partially, TFAP2C reexpression, indicating that the downmodulation of TFAP2 factors by miR-214, occurring during metastatic dissemination, is necessary to remove the direct transcriptional repression of TFAP2 on ALCAM promoter. Importantly, we previously proved that TFAP2C is responsible for many miR-214 pro-metastatic functions and that TFAP2C re-expression in miR-214-overexpressing cells was able to rescue miR-214-induced cell movement and early lung metastatic colonization (18) . Interestingly, this TFAP2-mediated regulation is similar to what previously shown for the ALCAM homologue MCAM-MUC-18 adhesion molecule in melanoma (42) .
Regarding the post-transcriptional control, we showed that miR-214 upregulates ALCAM expression by reducing another small non-coding RNA, miR-148b, which was predicted to directly target ALCAM.
In agreement with bioinformatics anticipations, we observed significant downmodulation of ALCAM protein following miR-148b overexpression. Direct targeting was proven by Luciferase reporter assays on wild type but not on miR-148b seed-mutants. Importantly, we observed decreased miR-148b levels following miR-214 overexpression in different melanoma cell lines and, viceversa, increased levels in miR-214-silenced cells. Significantly, miR-148b overexpression in miR-214-overexpressing cells was able to re-establish low ALCAM levels, as in control cells. Our results suggested a miR-on-miR regulatory loop between miR-148b and miR-214, in which miR-214 could control miR-148b transcription or processing or stability. Another miR-on-miR regulation was previously described for mouse miR-709 which binds on pri-miR-15a/16-1 thus preventing its processing (28) . By using the same approach, we looked for possible miR-214 recognition sites around miR-148b locus, but found only a non-statistically significant putative site, located downstream of pre-miR-148b. Instead, the observation that also pri-miR-148b was downmodulated following miR-214 overexpression and that 
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many putative TFAP2 binding sites were present in miR-148b locus, including a high affinity one in the potential promoter region, led us to investigate a possible transcriptional regulation. On this line, we and others (The ENCODE project) proved TFAP2 binding enrichment on this site by ChIP analyses. In addition, pri-and mature miR-148b expression increased following TFAP2A and TFAP2C overexpression. However, we cannot exclude additional regulations, such as post-transcriptional functions of TFAP2 or, since it is well known that miR-148/152 expression is controlled by promoter methylations (43) , possible miR-214-controlled epigenetic mechanisms.
In conclusion, our data indicate that miR-214-driven TFAP2 downregulation occurring during melanoma malignancy, controls ALCAM expression in a dual way: directly, at the transcriptional level, as well as indirectly, by controlling the expression of ALCAM-targeting miR-148b. These data are further reinforced by ours and others observations showing that ALCAM expression increases while TFAP2 decreases and that high levels of miR-214 anti-correlate with poor miR-148b expression during melanoma progression, as assessed in melanoma cell lines and tissues (18, 44) . Relevantly, we recently showed that miR-148b inhibits breast cancer progression, mainly by affecting cell movement and survival (45) . Similarly, and opposite to what shown for miR-214 (18), miR-148b considerably opposes melanoma cell movement, transendothelial migration and, to a lesser extent, survival to anoikis. More importantly, when miR-148b was upregulated in miR-214-overexpressing cells, it was able to rescue miR-214/ALCAM-mediated pro-metastatic effects on melanoma cell movement and early lung metastatic colonization.
Taken together, our data indicate that miR-214-driven ALCAM upregulation in metastatic melanoma cells depends on transcriptional (mediated by TFAP2) and post-transcriptional (mediated by miR- 
